APA (7th ed.) Citation

Dilan Askin Ozek, Elif Onat, Kazim Sahin, Mehmet Tuzcu, Merve Yilmaz Bozoglan, & Engin Sahna. (2023). Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways. Universidade de São Paulo.

Chicago Style (17th ed.) Citation

Dilan Askin Ozek, Elif Onat, Kazim Sahin, Mehmet Tuzcu, Merve Yilmaz Bozoglan, and Engin Sahna. Pre-treatment of the Beta3-adrenergic Receptor Agonist BRL37344 Reduces in Vivo Myocardial Ischemia/reperfusion Injury by Improving AMPK and SIRT1 Activity and by Suppressing MTOR and P70S6K Signaling Pathways. Universidade de São Paulo, 2023.

MLA (9th ed.) Citation

Dilan Askin Ozek, et al. Pre-treatment of the Beta3-adrenergic Receptor Agonist BRL37344 Reduces in Vivo Myocardial Ischemia/reperfusion Injury by Improving AMPK and SIRT1 Activity and by Suppressing MTOR and P70S6K Signaling Pathways. Universidade de São Paulo, 2023.